Status:
UNKNOWN
Should a Standard Lymphadenectomy Include the No. 16 Lymph Nodes for Patients With Pancreatic Head Adenocarcinoma.
Lead Sponsor:
Ruijin Hospital
Conditions:
Pancreatic Ductal Adenocarcinoma
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The aim of this study is to determine whether para-aortic lymph nodes(No.16) should be included in the lymphadenectomy during the pancreatoduodenectomy in order to improve the long-term survival of pa...
Detailed Description
Pancreatic cancer is now raised to the 7th leading cause of death. Surgical resection seems to be the unique curative therapy for pancreatic cancer. The pancreaticoduodenectomy is widely performed for...
Eligibility Criteria
Inclusion
- Pathologic diagnosis of pancreatic ductal adenocarcinoma
- Signed the informed consents
Exclusion
- Pathologic diagnosis of other pancreatic cancers
- Pre-operative anti-cancer treatment
- Recurrence patients
- Patients with contraindication(hepatic/ respiratory/ renal dysfunction, etc )
- Pre operative exam: Total bilirubin more than 250µmol/L
- AJCC stage IV
- Operation non radical
Key Trial Info
Start Date :
June 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04115527
Start Date
June 1 2018
End Date
December 31 2023
Last Update
October 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Ruijin Hospital
Shanghai, Shanghai Municipality, China, 200025